Home Newsfeeds Pfizer And BioNTech Begin Phase 1/2 Trial Of First-In-Class mRNA-Based Shingles Vaccine Program

Pfizer And BioNTech Begin Phase 1/2 Trial Of First-In-Class mRNA-Based Shingles Vaccine Program

https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-beginnen-phase-12-studie-mit-erstem-mrna

February 10, 2023

1 minute read

https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-beginnen-phase-12-studie-mit-erstem-mrna

Truist Securities Initiates Coverage On Inari Medical with Hold Rating, Announces Price Target of $87

September 13, 5:16 AM

Truist Securities analyst Richard Newitter initiates coverage on Inari Medical (NASDAQ:NARI) with a Hold rating and announces Price Target of $87.

August 1, 5:42 AM

Companies Reporting Before The Bell • Bon Natural Life (NASDAQ:BON) is projected to report earnings for its first quarter.

May 6, 1:01 PM

Crystal Zhu, former head of China Telco, Media & Tech IB at JPM, joins Morgan Stanley as co-head of APAC tech team. She'll focus on M&A and IPOs.

November 14, 9:06 PM

Major Wall Street indices closed in the red on Monday, in a reversal of last week’s rally driven by softer inflation data.